Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCEH1 | Q6PIU2 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30936758 | 0.84 | RIPK1 (0.40) | LMNAALDH1A1MAPK1MTNR1AMTNR1B | |
| SCHEMBL16682553 | 0.82 | MAPT (0.39) | L3MBTL1SMN1; SMN2ALDH1A1MAPK1MAPT | |
| SCHEMBL6437793 | 0.74 | MEN1 (0.42) | SMN1; SMN2ALDH1A1MTNR1AMTNR1B | |
| SCHEMBL23705585 | 0.74 | FPR2 (0.38) | AAK1SMN1; SMN2ALDH1A1MTNR1AMTNR1B | |
| SCHEMBL3313756 | 0.73 | ALDH1A1 (0.40) | LMNAL3MBTL1AAK1ALDH1A1MTNR1A | |
| SCHEMBL18286157 | 0.72 | KMT2A (0.47) | NCEH1LMNAL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL947274 | 0.72 | ALDH1A1 (0.44) | LMNAL3MBTL1POLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL571513 | 0.72 | NCEH1 (0.42) | NCEH1LMNAL3MBTL1POLBAAK1 | |
| SCHEMBL13765282 | 0.72 | CYP2A6 (0.42) | ALDH1A1MAPT | |
| SCHEMBL10000460 | 0.72 | LMNA (0.45) | NCEH1LMNAL3MBTL1ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557811-B2 | Dual-color imaging method of sodium/calcium activities using two-photon fluorescent probes and preparation method of two-photon fluorescent probes | Ajou University Industry—Academic Cooperation Foundation (KR) | 2013-10-15 | — | — | US | disclosed |
| US-8557811-B2 | Dual-color imaging method of sodium/calcium activities using two-photon fluorescent probes and preparation method of two-photon fluorescent probes | Ajou University Industry—Academic Cooperation Foundation (KR) | 2013-10-15 | — | — | US | disclosed |
| US-20120035360-A1 | DUAL-COLOR IMAGING METHOD OF SODIUM/CALCIUM ACTIVITIES USING TWO-PHOTON FLUORESCENT PROBES AND PREPARATION METHOD OF TWO-PHOTON FLUORESCENT PROBES | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION | 2012-02-09 | — | — | US | disclosed |
| US-20120035360-A1 | DUAL-COLOR IMAGING METHOD OF SODIUM/CALCIUM ACTIVITIES USING TWO-PHOTON FLUORESCENT PROBES AND PREPARATION METHOD OF TWO-PHOTON FLUORESCENT PROBES | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035360-A1 | DUAL-COLOR IMAGING METHOD OF SODIUM/CALCIUM ACTIVITIES USING TWO-PHOTON FLUORESCENT PROBES AND PREPARATION METHOD OF TWO-PHOTON FLUORESCENT PROBES | CACNB2, CA2, ATP2A2 | NCEH1 2140/4885LMNA 773/4885L3MBTL1 3676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.